SBIR/STTR Research Award

Encapsulated Vaccines Against Select Agents

Award identifier d36eca460d05528c23c0a8dba15cb0e2a1f2f0a324f3d604095efd4b25ba8b4dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,957

Program and phase

STTR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NANORELEASE TECHNOLOGIES, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
XX6JGNQJHSL3
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The ultimate goal of the research proposed is the development of vaccines against intracellular pathogens. The model system to be employed is the Brucella spp, a causative agent of infectious abortion in animals (Bang' s disease) and undulant fever, a chronic debilitating disease in humans. Historically, elimination of brucellosis as a public health threat has relied on the elimination of animal infection. However, the potential threat of bioterrorism or biowarfare use of this class B select agent underscores the need to develop direct intervention strategies to preserve public health. The long range goal is to develop an enabling technology for the enhancement and delivery of promising vaccines through controlled relea se. The objectives of this application are to entrap live, highly attenuated vaccine strains, in specialized coatings designed for controlled release, and test their efficacy in a mouse model. We propose that the use of controlled release vehicles can pote ntiate the use of safe but moderately protective strains and produce efficacious, marketable vaccines. We have several lines of strong preliminary data to support this work. These include i) Brucella attenuated strains developed through specific mutagene sis and characterized with regard to safety and efficacy in a mouse model and, ii) vaccination data documenting the performance of novel proteins as a robust erodible biopolymer in vaccine delivery systems. We will test our hypothesis with the following sp ecific aims: 1) Entrap target strains in capsule formulations enabling sustained release and 2) Test the safety and efficacy of these novel encapsulated strains in a mouse model.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2008–2011). Reported award amounts total $199,956. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.